Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

829.95INR
29 Jul 2016
Change (% chg)

Rs4.50 (+0.55%)
Prev Close
Rs825.45
Open
Rs825.00
Day's High
Rs839.80
Day's Low
Rs820.55
Volume
3,056,996
Avg. Vol
3,320,358
52-wk High
Rs966.00
52-wk Low
Rs704.00

Latest Key Developments (Source: Significant Developments)

Sun Pharma and Almirall signs license deal for Psoriasis treatment
Wednesday, 27 Jul 2016 10:32pm EDT 

Sun Pharmaceutical Industries Ltd : Almirall and Sun Pharma enter into a license agreement for Tildrakizumab in Europe for Psoriasis . To receive development & regulatory milestone payments, royalties, the terms of which are confidential .  Full Article

Almirall signs license deal with Sun Pharma for psoriasis treatment
Wednesday, 27 Jul 2016 11:57am EDT 

Almirall SA : Says enters into a license agreement with Sun Pharma Industries for tildrakizumab in Europe for psoriasis . Says to pay Sun Pharma an initial upfront payment of $50 million . Says Sun Pharma will be eligible to get milestone payments, sales milestone payments and royalties on net sales .Says phase-3 studies of tildrakizumab have recently been completed.  Full Article

Sun Pharma signs 410 mln rupees deal with RPG Life Sciences
Wednesday, 27 Jul 2016 06:57am EDT 

Sun Pharmaceutical Industries Ltd : Signed an agreement with RPG Life Sciences Ltd to divest seven prescription brands in India . Deal for a consideration of 410 million rupees . 7 divested brands include brands used for treatment of respiratory-track infections, urological disorders, cardiovascular diseases and brands in health supplements segment .  Full Article

Sun Pharma Industries gets USFDA nod for generic Crestor
Wednesday, 20 Jul 2016 02:25am EDT 

Sun Pharmaceutical Industries Ltd : Gets final approval from USFDA for generic Crestor .  Full Article

Sun Pharma enters licensing deal for SPARC's Elepsia XR
Sunday, 17 Jul 2016 10:35pm EDT 

Sun Pharmaceutical Industries Ltd : Sparc licenses elepsia xrtm(levetiracetam er tablets) to Sun pharma . Sparc to get up-front payment of $10 million from co . Sparc licenses elepsia xrtm to Sun pharma's unit . Sparc eligible for additional milestone payments, defined royalties linked to future sales of elepsia xr .  Full Article

Sun Pharmaceutical Industries launches Gemcitabine InfuSMART
Sunday, 10 Jul 2016 10:56pm EDT 

Sun Pharmaceutical Industries Ltd : Launches gemcitabine infusmart, ready-to-administer bag for oncology treatment . Product will have shelf life of 2 years . Infusmart rollout starts in europe,planned across 6 countries-netherlands,uk,spain,germany,italy & France over next few months .  Full Article

Taro Pharma CEO Kal Sundaram to return to Sun Pharma headquarters by the end of 2016
Wednesday, 6 Jul 2016 05:02pm EDT 

Taro Pharmaceutical Industries Ltd : Taro ceo Kal Sundaram to return to Sun Pharma headquarters by the end of 2016 . Sundaram informed taro's board of his intention to step down as ceo by end of current calendar year .Board will conduct a formal process to appoint a ceo for taro.  Full Article

Sun Pharma Industries approves buyback of 7.5 mln shares at 900 rupees/share
Monday, 27 Jun 2016 09:21am EDT 

Sun Pharmaceutical Industries Ltd :Approved buyback of 7.5 million shares at 900 rupees/share.  Full Article

Sun Pharmaceutical Industries approves buyback of equity shares
Thursday, 23 Jun 2016 10:33pm EDT 

Sun Pharmaceutical Industries Ltd : Board approves buyback of equity shares . Approved the buyback by the company of its fully paid up equity shares worth inr 6.75 billion .  Full Article

Sun Pharmaceutical Industries says co expects FY17 sales up 8-10 pct
Monday, 30 May 2016 11:34pm EDT 

Sun Pharmaceutical Industries Ltd : MD says expects FY 2017 sales up 8-10 percent . Exec says Department of Justice subpoena is "not a product specific query" . Further company coverage [SUN.NS] ((Bengaluru Newsroom; +91 80 6749 1130)).  Full Article

Photo

Exclusive: Teva, Mylan eye Pfizer's Brazil venture, sources say

SAO PAULO Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two people familiar with the process said.